Pure Global
NCT06044181

Peripheral Avascular Retina in Retinopathy of Prematurity

Long Term Management of Peripheral Avascular Retina in Retinopathy of Prematurity Evaluated by Fundus Fluorescein Angiography.
Assiut University·ClinicalTrials.gov·procedureNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Retinopathy of Prematurity
Drug/Device/Intervention
Diode laser photocoagulation.
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Assiut University
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
Nov 01, 2025
Enrollment
32 participants
Primary outcome

Number of eyes showing peripheral retinal active leakage.

Summary

Retinopathy of prematurity (ROP) is a widely known retinal vascular disorder in preterm
 infants and a leading cause of visual disability or blindness in children. Advances in
 antenatal care have resulted in an increase in the survival rate of infants with extremely
 low birth weight (BW). Approximately 90% of infants who develop ROP do so by a postmenstrual
 age of 46.3 weeks. In certain patients with or without treatment, the retina may fail to
 fully vascularize or may develop vascular abnormalities, thus demonstrating persistent
 avascular retina (PAR) or anomalous vessel findings at the periphery. Because of the advent
 of technologies such as ultrawide-field fluorescein angiography (UWFFA) persistent vascular
 abnormalities can be detected more readily and investigated.

ICD-10 classifications
Retinopathy of prematurityOther proliferative retinopathyBackground retinopathy and retinal vascular changesDiabetic retinopathyRetinal disorder, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06044181
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06044181 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Retinopathy of Prematurity. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.